Increased Fraction of Circulating Activated Platelets in Acute and Previous Cerebrovascular Ischemia

Armin J. Grau; Andreas Ruf; Axel Vogt; Christoph Lichy; Florian Buggle; Heinrich Patscheke; Werner Hacke

doi:10.1055/s-0037-1615191

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 80(02): 298-301
DOI: 10.1055/s-0037-1615191

Rapid Communication

Schattauer GmbH

Increased Fraction of Circulating Activated Platelets in Acute and Previous Cerebrovascular Ischemia

Armin J. Grau

¹From the Neurology Department, University of Heidelberg, Department of Clinical Chemistry, Städtisches Klinikum Karlsruhe, Germany

,

Andreas Ruf

¹From the Neurology Department, University of Heidelberg, Department of Clinical Chemistry, Städtisches Klinikum Karlsruhe, Germany

,

Axel Vogt

¹From the Neurology Department, University of Heidelberg, Department of Clinical Chemistry, Städtisches Klinikum Karlsruhe, Germany

,

Christoph Lichy

¹From the Neurology Department, University of Heidelberg, Department of Clinical Chemistry, Städtisches Klinikum Karlsruhe, Germany

,

Florian Buggle

¹From the Neurology Department, University of Heidelberg, Department of Clinical Chemistry, Städtisches Klinikum Karlsruhe, Germany

,

Heinrich Patscheke

¹From the Neurology Department, University of Heidelberg, Department of Clinical Chemistry, Städtisches Klinikum Karlsruhe, Germany

,

Werner Hacke

¹From the Neurology Department, University of Heidelberg, Department of Clinical Chemistry, Städtisches Klinikum Karlsruhe, Germany

› Author Affiliations

Abstract

Summary

Determination of circulating activated platelets may be helpful to estimate the prognosis and to stratify therapies in arterial vascular disorders including stroke. We used flow cytometry and phase contrast microscopy to study whether the fraction of platelets expressing p-selectin and CD63 and the fraction of platelets with shape change are increased in patients with acute and previous cerebrovascular ischemia.

The proportion of platelets expressing activation dependent antigens was higher in patients with acute (n = 24; p-selectin: 8.23 ± 4.21%; CD63: 3.53 ± 2.53%) and with previous cerebrovascular ischemia (n = 46; 3.86 ± 1.98%; 2.80 ± 1.79%) as compared to age- and sex-matched control subjects (n = 35; 2.17 ± 0.96%; 1.79 ± 0.75%; p ≤0.005, respectively). In patients with previous ischemia, there was no difference between treatment with aspirin (n = 25) or phenprocoumon (n = 21). Hypertension, diabetes mellitus and smoking were not associated with increased antigen expression (analysis of variance). The fraction of discoid platelets and platelet counts were not significantly different between groups.

Our results indicate increased expression of platelet neoantigens in acute and to a less degree in previous cerebrovascular ischemia. Ongoing platelet activation after cerebrovascular ischemia despite therapy with aspirin or phenprocoumon indicates that new anti-platelet drugs may be of benefit for these patients. Flow cytometry appears to be a useful tool to assess platelet function in cerebrovascular ischemia.

Full Text

References

References
1 Fisher M, Levine P, Fullerton A, Forsberg A, Duffy C, Hoogasian J, Drachman D. Marker proteins of platelet activation in patients with cerebrovascular disease. Arch Neurol 1982; 39: 692-5.
2 Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47: 1075-9.
3 Joseph R, D’Andrea G, Oster S, Welch K. Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents. Stroke 1989; 20: 38-44.
4 Tohgi H, Suzuki H, Tamura K, Kimura B. Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. Stroke 1991; 22: 17-21.
5 Holmsen H. Platelet secretion. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh I, Marder VJ, Salzman EW. eds. 2nd ed. JB Lippincott Company. Philadelphia; PA: 1987. pp 606-17.
6 De Bruijne-Admiraal LG, Modderman PW, Von dem Borne AEG, Sonnenberg A. P-selectin mediates Ca²⁺-dependent adhesion of activated platelets to many different types of leukocytes: Detection by flow cytometry. Blood 1992; 80: 134-42.
7 Damle NK, Klussman K, Dietsch MT, Mohagheghpour N, Aruffo A. GMP-140 (P-selectin/CD62) binds to chronically stimulated but not resting CD4+ T lymphocytes and regulates their production of proinflammatory cytokines. Eur J Immunol 1992; 22: 1789-93.
8 Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by p-selectin on adherent platelets. Nature 1992; 359: 848-51.
9 Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, Furie B. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci. USA 1994; 91: 8767-71.
10 Nagata K, Tsuji T, Todoroki N, Katagiri Y, Tanoue K, Yamazaki H, Hanai N, Irimura T. Activated platelets induce superoxide anion release by monocytes and neutrophils through p-selectin (CD62). J Immunol 1993; 151: 3267-73.
11 Ruf A, Patscheke H. Platelet induced neutrophil activation: platelet-expressed fibrinogen induces the oxidative burst in neutrophils by an interaction with CD11c/CD18. Brit J Haematol 1995; 90: 791-6.
12 Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252-5.
13 Metzelaar MJ, Wijngaard PLJ, Peters PJ, Sixma JJ, Nieuwenhuis HK, Cleverts HC. CD63 antigen. J Biol Chem 1991; 266: 3239-45.
14 Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 1983; 250: 2942-6.
15 Welin L, Svärdsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987; 317: 521-6.
16 Grau AJ, Buggle F, Steichen-Wiehn C, Heindl S, Banerjee T, Seitz R, Winter R, Forsting M, Werle E, Nawroth P, Becher H, Hacke W. Clinical and biochemical analysis in infection-associated stroke. Stroke 1995; 26: 1520-6.
17 Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and p-selectin expression. Sem Thrombos Hemostas 1995; 21: 146-51.
18 Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, Guillin MC, Eldor A. The procoagulant activity of red blood cells from patients with β-thalassemia major correlates with in vivo platelet activation. Brit J Hematol 1997; 98: 51-6.
19 Harrison P, Cramer EM. Platelet α-granules. Blood reviews 1993; 7: 52-62.
20 Stewart ME, Douglas JT, Lowe GDO, Prentice CRM, Forbes CD. Prognostic value of beta-Thromboglobulin in patients with transient cerebral ischemia. Lancet 1983; ii: 479-82.
21 Becker RC, Tracy RP, Bovill EG, Mann KG, Ault K. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III Thrombosis and Anticoagulation Group. Coron Artery Dis 1994; 5: 339-48.
22 Gawaz M, Neumann FJ, Ott I, Schiessler A, Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-37.
23 Gawaz M, Neumann FJ, Ott I, May A, Rüdiger S, Schömig A. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996; 76: 166-72.
24 Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/ macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23: 1367-79.
25 Nash GB. Adhesion between neutrophils and platelets: A modulator of thrombolytic and inflammatory events?. Thromb Res 1994; 74 (Suppl. 01) S3-S11.
26 Buttrum SM, Hatton R, Nash GB. Selectin-mediated rolling of neutrophils on immobilized platelets. Blood 1993; 82: 1165-74.
27 Yeo EL, Sheppard JAI, Feuerstein IA. Role of p-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (An injury vessel wall model). Blood 1994; 83: 2498-507.
28 Schömig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
29 Neumann FJ, Gawaz M, Dickfeld T, Wekinger A, Walter H, Blasini R, Schömig A. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997; 29: 1515-9.